Middle-term evolution of patients with advanced cutaneous T-cell lymphoma treated with high-dose recombinant interleukin-2

Arch Dermatol. 1997 May;133(5):656. doi: 10.1001/archderm.1997.03890410120021.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Follow-Up Studies
  • Humans
  • Interleukin-2 / administration & dosage*
  • Lymphoma, T-Cell, Cutaneous / therapy*
  • Remission Induction
  • Skin Neoplasms / therapy*

Substances

  • Interleukin-2